Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Cancer. 2017 Mar 27;123(16):3031–3039. doi: 10.1002/cncr.30693

Table 4.

Patterns of failure and outcomes of stereotactic ablative radiotherapy vs surgery for the treatment of clinical early-stage NSCLC reported in the current and other studies

Publication Total no. of pts Median follow-up (m) Prescribed dose/fractions LR (%) RR (%) DM (%) PFS (%) OS (%)
3y 5y 3y 5y 3y 5y 3y 5y 3y 5y
SABR studies
Baumann et al. (prospective, 2009) 10 57 35 45 Gy/3f 8 - 5c 16c 52 - 60 -
Timmerman et al. (prospective, 2010) a 11 59 34.4 54 Gy/3f 9.4 - 12.8b - 22.1 - 48.3 - 55.8 -
Onishi et al. (retrospective, 2011) 12 87 55 45–72.5 Gy/3–10f - 13.3 - 14.7 - 24.9 - - - 69.5
Senthi et al. (retrospective, 2012) 13 676 32.9 54–60 Gy/3f;
55–60 Gy/5f;
60 Gy/8f		 - 10.5 - 12.7 - 19.9 - - - ~32
Lagerwaard et al. (prospective database, 2012) 14 177 31.5 60 Gy/3,5,8f 7 - 9.7 - 9.7 - 81 - 84.7 -
Zheng et al. (retrospective, 2014)d15 Meta-analysis 28 BED10 ≥100 Gy 12.2b 16.1b - - - - 65.8 65.8 56.6 41.2
Ricardi et al. (retrospective, 2014) 17 196 30 48–60 Gy/3–8f 10.3 - 14.5 - 24.1 - 65.5 - 68 -
Nagata et al. (prospective, 2015) 16 100 (in) 47 48 Gy/4f 12.7 - 8c 23c 48.9 - 59.9 42.8
64 (op) 67 14.6 - 25c 32.8c 54.5 - 76.5 54
Spratt et al. (retrospective, 2015) 18 366 23 45–50 Gy/5f;
48 Gy/4f;
54–60 Gy/3f		 14.2 - 17.4 - 19.5 - - - ~53 -
Chang et al. (prospective, 2015) 1 31 40.2 54 Gy/3f; 50 Gy/4f; 60 Gy/5f 4 - 10 - 3 - 86 - 95 -
27 35.4 Lobectomy 0 - 4 - 9 - 80 - 79 -
Current study 65 86.2 50 Gy/4f 4.6 8.1 9.2 10.9 9.2 11.0 64.6 49.5 70.8 55.7
Surgery studies for clinical stage I NSCLC
Okada et al. (prospective nonrandomized, 2006) 31 262 >60 Lobectomy 6.9b,c 10.3c - 83.4 - 89.1
305 >60 SLR 4.9b,c 9.2c - 85.9 - 89.6
Whitson et al. (retrospective, 2007) 30 88 - Thoracotomy - - - - - - - - 77 64
59 - VATS 78 -
Crabtree et al. (PSM, 2010) 2 462 31 Surgery 6b - - - - - - - 68 55
76 19 SABR 11 - 3.9c - - - - 32 -
Verstegen et al. (PSM, 2013) 3 64 16 VATS 17.4b - - - 34.5 - 63.2 - 76.9 -
64 30 SABR 6.7b - - - 14.8 - 79.3 - 79.6 -
Port et al. (PSM, 2014) 4 76 35 Wedge±brachy 4b,c 5c 88 - 87 -
23 35 SABR 13b,c 17c 72 - 75 -
Landreneau et al. (PSM, 2014) 29 312 64.8 Segmentectomy 5.5b,c 14.8c - 70 - 54
312 64.8 Lobectomy 5.1b,c 11.6c - 71 - 60

– indicates the specific number was not provided.

a

55 patients were evaluable. The primary tumor failure rate was 2.4% at 3 years. Three additional patients had recurrence within the involved lobe.

b

Local-regional failure rate.

c

Actual recurrence rate instead of estimated cumulative 3-, 5-year recurrence rates.

d

A meta-analysis of 40 SABR studies (4850 patients) published after 2005. Local-regional control data were from 30 studies.

Abbreviations: LR, local recurrence; RR, regional recurrence; DM, distant metastasis; PFS, progression-free survival; OS, overall survival; m, month; y, year; f, fraction; SLR, sublobar resection; VATS, lobectomy by video-assisted thoracoscopic surgery; PSM, propensity-matched analysis; in, inoperable; op, operable.